Table 1 Clinical characteristics of patients with membranous nephropathy included in this study and control subjects

Number of patients and controls

6

6

6

5

Median age (years) (range)

63 (60‒67)

78 (41‒82)

45 (33‒61)

53 (45‒77)

Male:female

3:3

3:3

1:5

1:4

RLA2R antibody titer (positive: ≥ 14 RU/mL)*

36.8 (35.3–576.9)

0 (0–1.5)

Median proteinuria (g/gCr or g/day) at biopsy (range)

10.0 (5.3‒21.0)

3.7 (2.6 ‒23.7)

0.5 (0.2‒5.5)

0.7 (0.1‒0.9)

Median maximum level during BCL therapy (range)

4.8 (1.7‒8.8)

Median minimum level after BCL withdrawal (range)

0.2 (0.1‒0.7)

Median serum albumin (g/dL) (range)

2.2 (1.2‒2.9)

3.0 (1.0‒3.2)

3.1 (2.8‒4.0)

4.3 (3.5‒4.5)

Nephrotic syndrome, n

6

4

2

Median serum Cr (mg/dL) (range)

0.64 (0.49‒0.90)

0.58 (0.39‒0.90)

0.40 (0.40‒0.86)

0.67 (0.60‒0.90)

Median eGFR (mL/min/1.73 m²) (range)

72.1 (65.7‒94.4)

99.7 (74.9‒124.6)

131 (66.4‒143.2)

72.1 (66.9‒81.6)